The Management of Decompensated Heart Failure Resulting in Hospitalization: Proceedings from an Expert Meeting To Review Current Concepts and To Define Future Directions
Tezosentan in patients with acute heart failure and acute coronary syndromes: Design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4),☆☆,

https://doi.org/10.1067/mhj.2003.156Get rights and content

Abstract

Am Heart J 2003;145:S58-9.

Section snippets

Design and methods, end points, statistical considerations

RITZ-4 was a multicenter, randomized, double-blind, placebo-controlled trial, sponsored by Actelion, that investigated the use of tezosentan versus placebo in patients with acute heart failure in the setting of ACS. Patients were randomized in a 1:1 fashion to receive tezosentan or placebo for at least 24 and up to 48 hours. Patients randomized to the tezosentan group received 25 mg/h intravenously for 1 hour followed by 50 mg/h for 23 and up to 48 hours of treatment. The primary efficacy end

References (13)

There are more references available in the full text version of this article.

Cited by (11)

View all citing articles on Scopus

Reprint requests: Christopher M. O'Connor, MD, Duke Clinical Research Institute, 2400 N Pratt St, 0311 Terrace Level, Durham, NC 27705.

☆☆

E-mail: [email protected]

0002-8703/2003/$30.00 + 0

View full text